Back to Browse Journals » Biologics: Targets and Therapy » Volume 2 » Issue 4

The insulin-like growth factor system and its receptors: A potential novel anticancer target

Authors Colin R. Lindsay, T R Jeffry Evans

Published Date September 2008 Volume 2008:2(4) Pages 855—864

DOI http://dx.doi.org/10.2147/BTT.S3841

Published 18 September 2008

Colin R. Lindsay1, T R Jeffry Evans1,2

1Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom; 2University of Glasgow, CR-UK Beatson Laboratories, Garscube Estate, Glasgow, United Kingdom

Abstract: The current generation of novel anticancer therapies that are in preclinical and clinical development are based on exploiting our increasing understanding of the molecular and cellular basis of cancer development and progression. Accelerated rates of cell division and proliferation have been postulated to predispose to the development of malignant disease. The insulin-like growth factor (IGF) signaling system has an important physiological role in regulating cellular proliferation and apoptosis. This function has led to considerable interest in its relevance to neoplasia over the last decade. In this review, we give an overview of the IGF system physiology, discuss the epidemiological significance of IGF signaling and neoplasia, and review the preclinical and clinical studies in targeting IGF receptors as cancer therapies.

Keywords: insulin, growth factor, IGF-1, clinical trials

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Scleral buckling procedure with chandelier illumination for pediatric rhegmatogenous retinal detachment

Yokoyama T, Kanbayashi K, Yamaguchi T

Clinical Ophthalmology 2015, 9:169-173

Published Date: 23 January 2015

Smart Grid and nanotechnologies: a solution for clean and sustainable energy

Markovic DS, Branovic I, Popovic R

Energy and Emission Control Technologies 2015, 3:1-13

Published Date: 23 January 2015

Comparison of single injection and three monthly injections of intravitreal bevacizumab for macular edema associated with branch retinal vein occlusion

Ito Y, Saishin Y, Sawada O, Kakinoki M, Miyake T, Sawada T, Kawamura H, Ohji M

Clinical Ophthalmology 2015, 9:175-180

Published Date: 23 January 2015

A medical costs study of older patients with acute myocardial infarction and metabolic syndrome in hospital

Fan GQ, Fu KL, Jin CW, Wang XZ, Han L, Wang H, Zhong M, Zhang Y, Zhang W, Wang ZH

Clinical Interventions in Aging 2015, 10:329-337

Published Date: 23 January 2015

Corrigendum

De Caterina AR, Harper AR, Cuculi F

Vascular Health and Risk Management 2012, 8:443-445

Published Date: 19 July 2012

Erratum

RA Kurt, K Gündüz

Clinical Ophthalmology 2010, 4:981-982

Published Date: 6 September 2010